A Phase 1, Safety, Tolerability, and Distribution Study of a Microdose of Radiolabeled BIIB067 Co-administered With BIIB067 to Healthy Adults
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 21 Aug 2019
Price : $35 *
At a glance
- Drugs Tofersen (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions
- Sponsors Biogen
- 27 Jun 2019 Planned End Date changed from 2 Dec 2019 to 5 Apr 2020.
- 27 Jun 2019 Planned primary completion date changed from 2 Dec 2019 to 6 Jan 2020.
- 27 Jun 2019 Status changed from recruiting to active, no longer recruiting.